Feb 20, 2026 Experienced researchers know something that newcomers to compounded semaglutide often miss
Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease
doi: 10.1016/j.metabol.2010.09.010 57 SimpsonSHMajumdarSRTsuyukiRTEurichDTJohnsonJA
Improved metabolic health may enhance mood and focus
However, its off-label use for performance enhancement in bodybuilding falls outside approved indications and may carry legal and regulatory risks
MS: literature search, data analysis, and original draft preparation